Progressive multiple sclerosis (MS) is a form of disease causes long-term disability but there no many treatment options. In a phase 2 trial involving patients with progressive MS, ibudilast provided new hope for slower progression of brain atrophy. The study also demonstrated that the main side effects of the drug were headaches, depression and gastrointestinal problems, says a new study supported by NINDS and published in NEJM.